Latest Antibody News

New York Mesothelioma Lawyer Applauds Breakthrough Cancer ResearchJoseph W. Belluck of New York’s Belluck & Fox, LLP, says a new study offers the promise of earlier detection of mesothelioma and a new method of treatment. New York, NY (PRWEB) May 26, 2012 New York mesothelioma lawyer Joseph W. Belluck voiced optimism today about new medical research that examines the role played by a protein that has been linked to the development of malignant mesotheliom...

Sanofi and Regeneron Announce Publication of Positive Phase 2 Results for Lipid-Lowering PCSK9 Antibody in The LancetPARIS and TARRYTOWN, New York, May 26, 2012 /PRNewswire/ -- Sanofi (EURONEXT: SAN and NYSE: SNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced additional positive results from a Phase 2 trial of SAR236553/REGN727 (Study 1003, NTC01266876) in patients with heterozygous familial hypercholesterolemia (heFH). SAR236553/REGN727 is a subcutaneously administered, fully-human antibod...

Combo Tx Better in HIV-Related LymphomaCHICAGO (MedPage Today) -- Adding the monoclonal antibody rituximab (Rituxan) to chemotherapy improves outcomes for HIV patients diagnosed with non-Hodgkin's lymphoma, researchers reported.

New Mesothelioma Clinical Trial Discussed in Open-to-Public TeleconferenceOn Thursday, May 24, 2012, the Mesothelioma Applied Research Foundation (Meso Foundation) hosted Dr. Raffit Hassan from the National Cancer Institute (NCI) in an interview about his most recent clinical trial for pleural and peritoneal mesothelioma patients. The call was part of the organization’s “Meet the Experts” series. Washington, DC (PRWEB) May 25, 2012 Last night, as part of the “M...

European Medicines Agency Confirms Positive Benefit-Risk Balance of MabtheraBatches produced at the Vacaville manufacturing site do not pose risk to public health Following a quality review of the genetically engineered monoclonal antibody MabThera, the European Medicines Agency’s Committee for Medicinal Products...

News and press releases: European Medicines Agency confirms positive benefit-risk balance of MabTheraFollowing a quality review of the genetically engineered monoclonal antibody MabThera, the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has concluded that the batches of the active substance of MabThera, rituxim...

Oncobiologics Fills Key Leadership Positions and Names Scientific Advisory BoardCRANBURY, N.J., May 25, 2012 /PRNewswire/ -- Oncobiologics, Inc. announced today that it has filled two important leadership positions with established biopharmaceutical industry experts. Stephen J. McAndrew, Ph.D. is now Vice President, Business Development and Vincent J. Benn, Ph.D. has joined the company as Vice President, Clinical & Regulatory Affairs. The company also announced its n...

Biologic Works in Ulcerative Colitis (CME/CE)SAN DIEGO (MedPage Today) -- A new gut-selective monoclonal antibody showed significant benefits in patients with refractory ulcerative colitis, a researcher reported here.

Brentuximab vedotin effective in large-cell lymphoma(HealthDay) -- More than half of patients with relapsed or refractory systemic anaplastic large-cell lymphoma (ALCL) treated with the CD30-directed antibody-drug conjugate brentuximab vedotin achieve a complete remission, according to the results of...

SD Life Sciences Roundup: Takeda Consolidates, Startups Raise CashIt’s been a busy week for startup funding, with Obalon Therapeutics, Aperio Technologies, Topera, and Ivera Medical closing on financing deals. We’ve also got drug development news from Ocera Therapeutics and MediciNova. —Japan’s Takeda Pharm...

High-throughput antibody sequencing reveals genetic evidence of global regulation of the naïve and memory repertoires that extends across individuals

Health Canada approves Biogen Tysabri label changeThe Health Canada has approved a label change for Biogen Idec's Tysabri to include anti-JC virus (JCV) antibody status as a risk factor for patients with multiple sclerosis (MS).

Anti-IL-17 Receptor Antibody AMG 827 Leads to Rapid Clinical Response in Subjects with Moderate to Severe Psoriasis: Results from a Phase I, Randomized, Placebo-Controlled Trial

Donor-specific HLA-DQ antibodies may contribute to poor graft outcome after renal transplantation

AbD Serotec launches new HuCAL antibodies for development of novel antibody therapeuticsAbD Serotec, MorphoSys AG’s division for research and diagnostic antibodies, is to launch a series of novel anti-drug antibodies (ADAs) as diagnostic reagents. Starting with the recent launch of fully human, recombinant antibodies binding Rituximab...

Proteomics-Based Platform for Monoclonal Antibody Preparation May Replace Hybridoma TechniquesA new proteomics-based tool for preparation of highly purified monoclonal antibodies is now available for biotech and other life...

Cellectricon Launches Cellaxess® Elektra Discovery PlatformGOTHENBURG, Sweden, May 24, 2012 /PRNewswire/ -- Cellectricon is pleased to announce the new Cellaxess Elektra Discovery Platform which represents a revolutionary development in automated electric field manipulation of adherent cells. Developed in close collaboration with leading pharmaceutical and biotechnology companies, the platform is highly diverse and can be applied to a wide variety of cel...

Canine VacciCheck(R) Developed by Biogal was Highly Recommended in Articles Published in the Chicago Tribune and on BBC RadioKIBBUTZ GALED, Israel, May 24, 2012 /PRNewswire/ -- An interview recently published in the Chicago Tribune, addresses the use of Canine VacciCheck®, developed by Biogal, as a way to titer test dogs for core canine vaccines. In the article, Professor Schultz from the University of Wisconsin refers to Canine VacciCheck®: "One way to insure comfort for pet owners and veterinarians alike i...

Health Canada accepts Seattle Genetics' new drug submission for AdcetrisSeattle Genetics has announced that Health Canada has accepted for review a new drug submission (NDS) for its antibody-drug conjugate Adcetris (brentuximab vedotin) for use in relapsed Hodgkin lymphoma (HL) and systemic anaplastic large cell.....

Nanosmart(R) Pharmaceuticals Welcomes New Vice President Of R&DORANGE COUNTY, Calif., May 24, 2012 /PRNewswire/ -- Dr. James Smith, President of NanoSmart Pharmaceuticals, Inc., a California corporation developing a novel drug-delivery platform for cancer pharmaceuticals, announced today that the company has added Dr. Paul Glidden as Vice President of Research and Development. "Dr. Glidden has worked for over 20 years developing new chemical and mole...

Immune Pharmaceuticals, Yeda Partner on Her3 Antibody Development

AbD Serotec to introduce HuCAL anti-drug antibodiesAbD Serotec, MorphoSys' division for research and diagnostic antibodies, is set to introduce a series of the human combinatorial antibody library (HuCAL) anti-drug antibodies supporting the development of novel antibody therapeutics.

Gallus BioPharmaceuticals Completes Initial $20 Million Expansion of Early-Phase Clinical Manufacturing FacilityGallus BioPharmaceuticals—a leading provider of contract services to biopharmaceutical companies for process development, clinical and commercial manufacturing—completed a $20 million expansion of clinical manufacturing and process development facilities at its St. Louis, MO site. St. Louis, MO (PRWEB) May 24, 2012 Gallus’s new Clinical Services Suite (CSS) will operate under cGMP for Phase...

Preliminary results from Celldex’s CDX-011 Phase 2b breast cancer studyCelldex Therapeutics, Inc. today announced preliminary results from the Company's randomized Phase 2b EMERGE study of CDX-011 (glembatumumab vedotin) antibody drug conjugate in patients with glycoprotein NMB (GPNMB) expressing, advanced, heavily pret...

Antibody-drug conjugate shrinks some breast cancer tumors-study

0 1 2 3 4 ›»

buy Antibody market research data and corporate reports now Advertisement